Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Immune Checkpoint Inhibitors (ICI)-Related Dermatitis 1COVID-19 1

Interventions

Cyclophosphamide 45fludarabine phosphate 39Peripheral Blood Stem Cell Transplantation 35Busulfan 34Antilymphocyte Serum 26Tacrolimus 25Cyclosporine 25Methotrexate 23Filgrastim 23Mycophenolic Acid 22Radiotherapy 21Melphalan 17Etoposide 15Cytarabine 15Whole-Body Irradiation 14Methylprednisolone 13Cord Blood Stem Cell Transplantation 12Azacitidine 9Specimen Handling 8Biopsy 8ruxolitinib 7Sirolimus 7Cyclosporins 7Alemtuzumab 7Thiotepa 6Decitabine 6sargramostim 5Rituximab 5fludarabine 4Tretinoin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myelodysplastic-Myeloproliferative Diseases × Janus Kinase Inhibitors × Clear all
NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutchinson Cancer Center

Phase 2 Recruiting
50 enrolled
Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡